Dry AMD Program

About CHS Pharma

CHS Pharma is a private, preclinical-stage biotech company targeting multi-billion dollar markets in neurology, ophthalmology, and dermatology with novel small molecule therapies. The company highlights programs aimed at reversing the effects of ischemic stroke and mitigating dry macular degeneration, positioning itself for strategic partnerships and investment. While demonstrating scientific activity through publications and intellectual property, the company appears to be in an early development phase with a lean operational structure.

Therapeutic Areas